Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial

Trial Profile

Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Varenicline (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Acronyms EVITA
  • Most Recent Events

    • 26 Mar 2018 Results evaluating effect of varenicline (Champix) in smoking cessation 52 weeks after acute coronary syndrome, published in the CMAJ: Canadian Medical Association Journal.
    • 19 Apr 2016 Results published in the Annals of Internal Medicine
    • 14 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top